Statement for the prevention of stroke and systemic embolism in
adult patients with non-valvular atrial fibrillation
May 2015 update
This statement was first developed in April
2012 to support the safe and effective introduction of a new class
of medicines, namely the novel oral anticoagulants (NOACs) to
There are now three NOACs available for use in
NHSScotland (dabigatran, rivaroxaban and apixaban), each with
different efficacy and safety profiles. Local prescribing policies
are now being developed to agree choice and use of NOACs.
The statement will not be refreshed
but will remain as an information source for use by services that
require to review their arrangements for use of NOACs
The April 2012 statement is as follows:
Dabigatran etexilate (Pradaxa®) and rivaroxaban (Xarelto®)
Healthcare Improvement Scotland has been providing national
leadership and support for safe and effective use of the new oral
anticoagulants, dabigatran etexilate (Pradaxa®) and rivaroxaban
(Xarelto®) in NHSScotland via the development of a
national statement on their use.
The statement identifies those patient groups that should be
considered for dabigatran, rivaroxaban or existing anticoagulants,
such as warfarin.
The statement has been issued via each NHS boards’ Area
Drug and Therapeutic Committee (ADTC).
Published Date: 30 April 2012